Literature DB >> 17021670

Increased seropositivity of Helicobacter pylori cytotoxin-associated gene-A in Behçet's disease.

Teoman Zafer Apan1, Ragip Gürsel, Alp Dolgun.   

Abstract

Behçet's disease is a systemic vasculitic syndrome with unknown etiology. The aim of the present study was to compare the Helicobacter pylori seropositivity and cytotoxin associated gene-A status in patients with Behçet's disease. Ninety-one patients with Behçet's disease and 83 age- and sex-matched persons with or without any gastrointestinal complaints were included in the study. Demographic characteristics and H. pylori IgG, IgM, and cytotoxin-associated gene-A IgG status of the Behçet's disease and the control groups were analyzed. The influence of eradication therapy on clinical findings was also determined. The prevalence of H. pylori IgG seropositivity was slightly but not significantly higher in patients with Behçet's disease compared to the controls [72 (79.1%) vs 56 (67.5%), (p = 0.082)]. The prevalence of cytotoxin-associated gene A positivity was significantly higher in Behçet's disease compared to the controls [59 (64.8.%) vs 32 (38.5%), respectively, (p = 0.002)]. Eradication of H. pylori has significantly decreased clinical manifestations such as oral and genital ulceration, arthritis/arthralgia, and cutaneous findings of Bahçet's disease. Our study indicates that H. pylori may be involved in the pathogenesis of Behçet's disease or disease activity might be enhanced due to induced inflammation or altered immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021670     DOI: 10.1007/s10067-006-0416-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  29 in total

1.  Helicobacter pylori and Behçet's disease.

Authors:  O Avci; E Ellidokuz; I Simşek; B Büyükgebiz; A T Güneş
Journal:  Dermatology       Date:  1999       Impact factor: 5.366

2.  Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.

Authors:  Francis K L Chan; K F To; Justin C Y Wu; M Y Yung; W K Leung; Timothy Kwok; Y Hui; Henry L Y Chan; Cynthia S Y Chan; Elsie Hui; Jean Woo; Joseph J Y Sung
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

Review 3.  Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

4.  Analyses of the cag pathogenicity island of Helicobacter pylori.

Authors:  N S Akopyants; S W Clifton; D Kersulyte; J E Crabtree; B E Youree; C A Reece; N O Bukanov; E S Drazek; B A Roe; D E Berg
Journal:  Mol Microbiol       Date:  1998-04       Impact factor: 3.501

5.  Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease.

Authors:  Y Imamura; M S Kurokawa; H Yoshikawa; K Nara; E Takada; C Masuda; S Tsukikawa; S Ozaki; T Matsuda; N Suzuki
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

6.  Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis.

Authors:  M Mayr; S Kiechl; J Willeit; G Wick; Q Xu
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

7.  Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet's syndrome.

Authors:  T Lehner; E Lavery; R Smith; R van der Zee; Y Mizushima; T Shinnick
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

8.  CagA and VacA: virulence factors of Helicobacter pylori in Thai patients with gastroduodenal diseases.

Authors:  V Mahachai; P Tangkijvanich; N Wannachai; P Sumpathanukul; P Kullavanijaya
Journal:  Helicobacter       Date:  1999-09       Impact factor: 5.753

Review 9.  The role of heat shock proteins in Behçet's disease.

Authors:  H Direskeneli; G Saruhan-Direskeneli
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

10.  Comparison of genotyping of Helicobacter pylori cagA and vacA virulence genes from gastric biopsies and stool specimens.

Authors:  Liviu A Sicinschi; Pelayo Correa; Barbara G Schneider
Journal:  Helicobacter       Date:  2003-12       Impact factor: 5.753

View more
  5 in total

Review 1.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

Review 2.  Helicobacter pylori and autoimmune disease: cause or bystander.

Authors:  Daniel S Smyk; Andreas L Koutsoumpas; Maria G Mytilinaiou; Eirini I Rigopoulou; Lazaros I Sakkas; Dimitrios P Bogdanos
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

3.  High prevalence of Helicobacter pylori infection in Behcet's disease.

Authors:  Kamran B Lankarani; Mohammad Reza Ravanbod; Elham Aflaki; Mohammad Ali Nazarinia; Akbar Rajaee
Journal:  BMC Gastroenterol       Date:  2014-03-31       Impact factor: 3.067

Review 4.  Helicobacterpylori Infection-A Risk Factor for Irritable Bowel Syndrome? An Updated Systematic Review and Meta-Analysis.

Authors:  Ziyan Wang; Yuhua Liu; Yinglong Peng; Liang Peng
Journal:  Medicina (Kaunas)       Date:  2022-08-02       Impact factor: 2.948

5.  Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case-control frequency-matched study.

Authors:  Lei Qin; Yi-Wei Kao; Yueh-Lung Lin; Bou-Yue Peng; Win-Ping Deng; Tsung-Ming Chen; Kuan-Chou Lin; Kevin Sheng-Po Yuan; Alexander T H Wu; Ben-Chang Shia; Szu-Yuan Wu
Journal:  Cancer Med       Date:  2018-07-15       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.